Provisions for Drug Registration.docx
- 文档编号:9997887
- 上传时间:2023-02-07
- 格式:DOCX
- 页数:32
- 大小:33.21KB
Provisions for Drug Registration.docx
《Provisions for Drug Registration.docx》由会员分享,可在线阅读,更多相关《Provisions for Drug Registration.docx(32页珍藏版)》请在冰豆网上搜索。
ProvisionsforDrugRegistration
ProvisionsforDrugRegistration
(SFDAOrderNo.28)
ProvisionsforDrugRegistration
ChapterI
GeneralProvisions
Article1TheProvisionsareformulatedforthepurposesofensuringthesafety,efficacyandqualityofdrugsandregulatingdrugregistrationinaccordancewiththeDrugAdministrationLawofthePeople'sRepublicofChina(hereinafterreferredtoastheDrugAdministrationLaw),AdministrativePermissionLawofthePeople'sRepublicofChina(hereinafterreferredtoasAdministrativePermissionLaw)andtheRegulationsforImplementationoftheDrugAdministrationLawofthePeople'sRepublicofChina(hereinafterreferredtoastheRegulationsforImplementationoftheDrugAdministrationLaw).
Article2TheProvisionsapplytotheapplicationsfordrugclinicaltrial,drugproductionorimport,andconductingdrugapproval,relevanttestingfordrugregistration,orregulationthereof,withintheterritoryofthePeople'sRepublicofChina.
Article3DrugregistrationreferstotheprocessofreviewandapprovalonwhichtheStateFoodandDrugAdministration,inaccordancewiththeofficialprocedures,evaluatesthesafety,efficacyandqualityofthedrugsappliedformarketing,anddecideswhetherornottoapprovesuchanapplication.
Article4TheStateencouragestheresearchanddevelopmentofnewdrugsandadoptsthespecialreviewandapprovalwithrespecttoinnovativedrugs,newdrugsforseriousandlife-threateningdiseasesandtoaddressunmetmedicalneedsanddrugs.
Article5TheStateFoodandDrugAdministrationisinchargeofdrugregistrationnationwide,andresponsibleforreviewingandapprovingtheclinicaltrial,productionandimportationofdrugs.
Article6Thedrugregistrationshallfollowtheprinciplesofopenness,fairnessandjustice.
TheStateFoodandDrugAdministrationadoptsthesystemofcollectiveresponsibilityofthechiefreviewers,thesystemofpublicizingandchallengingrelevantpersons,andthesystemofresponsibilitytracing,withsocialsupervisioninsuchproceduresasacceptance,inspection,reviewandapprovalandsending.
Article7Intheprocessofdrugregistration,thedrugregulatorydepartmentshallmakeknowntothegeneralpublic,andholdhearingson,thematterswhichitdeemsofvitalimportanceandinvolvingpublicinterestsforthegrantingofpermission.
Priortomakingthedecisionofadministrativelicensingthathasadirectbearingonthevitalinterestbetweentheapplicantandtheotherparty,thedrugregulatorydepartmentshallinformtheapplicantandtheinterestedpartyoftheirrightsofrequestingforhearings,makingstatementsandargues.
Article8Thedrugregulatorydepartmentshallprovidetheapplicantwithaccesstoinformationonthestatusoftheacceptance,examination,inspection,reviewandapprovalofdrugregistrationapplicationandthefinalresolution.
Thedrugregulatorydepartmentshallpublicizethefollowinginformationonitsofficialwebsitesorattheofficialpremisesforacceptingapplications:
(1)theitems,procedures,feesandtheirbasis,andtimelinesofthedrugregistration,indexofallthedataneededtobesubmittedandmodeltextoftheapplicationform;
(2)thenamelistandotherrelevantinformationonthepersonsinvolvedintheacceptance,examination,inspection,reviewandapprovalofdrugregistration;and
(3)generalinformationaboutcategoriesofapproveddrugs,etc.
Article9Thedrugregulatorydepartment,relevantinstitutionsandpersonsinvolvedinthedrugregistrationhaveanobligationtokeepthetechnicalsecretsandtrialdatasubmittedbytheapplicantconfidential.
ChapterII
ApplicationforDrugRegistration
Article10Anapplicantfordrugregistration(hereinafterreferredtoasapplicant)referstotheinstitutionthatsubmitsadrugregistrationapplicationandassumescorrespondinglegalliability.
AdomesticapplicantshallbeaninstitutionlegallyregisteredwithintheterritoryofPeople'sRepublicofChinathatindependentlyassumescivilliabilityandanoverseasapplicantshallbealegaloverseasdrugmanufacturer.Whereanoverseasapplicantappliesforimportdrugregistration,itshallbedonebyitsbranchorentrustedagencywithintheterritoryofPeople'sRepublicofChina.
Thepersonswhohandletheapplicationfordrugregistrationshallhaveprofessionalknowledgeandbefamiliarwiththelawsandregulationson,andthetechnicalrequirementsfor,drugregistration.
Article11Drugregistrationapplicationsincludeapplicationsfornewdrugs,genericdrugs,importdrugsandtheirsupplementaryapplicationsaswellasre-registrationapplications.
Applicationsofdomesticapplicantsshallbehandledaccordingtotheproceduresandrequirementsfornewdrugsorgenericdrugs,whereasapplicationsofoverseasapplicantsshallbehandledaccordingtothoseforimportdrugs.
Article12ApplicationfornewdrugsreferstoapplicationforregistrationofdrugsthathavenotbeenmarketedwithintheterritoryofPeople'sRepublicofChina.
Applicationforchangingdosageformorrouteofadministration,orclaiminganewindicationformarketeddrugs,shallbesubmittedastheprocessofnewdrugapplication.
ApplicationforgenericdrugsreferstoregistrationapplicationforproducingthedrugshavingexistingnationaldrugstandardwhichisapprovedtobemarketedbytheStateFoodandDrugAdministration,whereastheapplicationforbiologicalproductsshallbesubmittedastheprocessofnewdrugapplication.
ApplicationforimportdrugsreferstoregistrationapplicationfordrugsmanufacturedabroadtobemarketedwithintheterritoryofthePeople'sRepublicofChina.
Supplementaryapplicationreferstoapplicationforvariation,addition,orcancellationoftheitemsorcontentsapprovedintheoriginalapplicationfornewdrug,genericdrugorimportdrug.
Re-registrationapplicationreferstoapplicationforcontinuedproductionorimportationofadrugaftertheexpirationofthevalidtermofthedrugapprovaldocument.
Article13Theapplicantshallprovidesufficientandreliableresearchdatatoprovethesafety,efficacyandqualityofthedrug,andbeliablefortheauthenticityofallthedossierssubmitted.
Article14Thecitedliteratureofthedossierofdrugregistrationshallindicatethetitleofworksorthename,volumenumber,issueandpageofthejournal.Wherethecitedreferencesarenotpublished,anauthor'spermissionshallbeprovided.Forforeignliteratures,Chinesetranslationshallbeprovidedasrequired.
Article15TheStateFoodandDrugAdministrationshallobeythedevelopmentplanandpoliciesonthepharmaceuticalindustryconstitutedbytheState,andmayconductassessmenttothemarketvalueofdrugs.
Article16Intheprocessofdrugregistration,thedrugregulatorydepartmentshallconducton-siteinspectionandcausalinspectiontothenon-clinicalstudiesandclinicaltrials,aswellasproductionsiteinspectionforthepre-marketingapprovaltoconfirmtheauthenticity,precisionandintegrityofthedossiersubmitted.
Article17Wheretwoormoreinstitutionsjointlyapplyfordrugs,theapplicationshallbesubmittedtothedrugregulatorydepartmentoftheprovince,autonomousregion,ormunicipalitydirectlyundertheCentralGovernment,inwhichthedrugmanufacturerislocated;wheretheapplicantsarealldrugmanufacturers,theapplicationshallbesubmittedtothedrugregulatorydepartmentoftheprovince,autonomousregion,ormunicipalitydirectlyundertheCentralGovernment,inwhichthemanufacturerofpharmaceuticalpreparationsislocated;wherenoneoftheapplicantsisadrugmanufacturer,theapplicationshallbesubmittedtothedrugregulatorydepartmentoftheprovince,autonomousregion,ormunicipalitydirectlyundertheCentralGovernment,inwhichthesiteforpilotproductionofdrugsamplesislocated.
Article18AnapplicantshallprovidetheinformationonpatentanditsownershipoftheapplicantorotherpartiesinChina,inrespectofthedrugappliedforregistration,itsformula,manufacturingprocessesand/oruses,etc.WhereanotherpartyownsthepatentinChina,theapplicantshallprovideastatementofnon-infringement.Thedrugregulatorydepartmentshallpublishtheinformationorthestatementsubmittedbytheapplicantonitsofficialwebsite.
Whereapatentdisputeoccursintheprocessofdrugregistration,itshallbesettledinaccordancewithrelevantlawsandregulationsonpatent.
Article19ForadrugpatentedinChina,applicantsotherthanthepatenteemaysubmittheapplicationforregistrationtwoyearspriortotheexpirydateofthepatent.TheStateFoodandDrugAdministrationshallreviewthedrugapplicationinaccordancewiththeProvisions,andaftertheexpirydateofthepatent,checkandissuethedrugapprovalnumber,ImportDrugLicenseoraPharmaceuticalProductLicenseiftheapplicationconformswiththeprovisions.
Article20InaccordancewiththeprovisionsinArticle35oftheRegulationsforImplementationoftheDrugAdministrationLaw,whereamanufacturerordistributorsubmitsundiscloseddrugexperimentalandotherdatawhichareindependentlyacquiredinordertoobtainapprovalforproductionormarketingofthedruginquestionwhichcontainsanynewchemicalentity,theStateFoodandDrugAdministrationshall,withinsixyearsfromtheapprovaldateofthedrug,rejectanyapplicationmadebyanyotherapplicantsbyusingtheundiscloseddataofthedruginquestionwithoutpermissionoftheoriginalapplicantwhohasobtainedthedrugapproval,unlessthedatasubmittedareindependentlyacquiredbytheapplicantsotherthantheoriginalone.
Article21Pre-clinicaldrugstudyfordrugregistrationappl
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- Provisions for Drug Registration
![提示](https://static.bdocx.com/images/bang_tan.gif)